DESIGN AND SYNTHESIS OF SELECTIVE KINASE INHIBITORS

选择性激酶抑制剂的设计与合成

基本信息

  • 批准号:
    2883041
  • 负责人:
  • 金额:
    $ 22.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-03-01 至 2000-02-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: The PI reports that the disruption of cellular signal transduction via protein kinase (PK) malfunction has been related to the onset of several disease states, including: rheumatoid arthritis, systemic lupus erythematosis, diabetes mellitus, and Alzheimer's disease. He notes that while PK inhibition is a logical target for chemotherapeutic intervention, the structural homology among the many PK isozymes has impeded the development of specific and hence therapeutically useful inhibitors. It is indicated that some specificity has been achieved in the area of indolocarbazoles and hence the archetypal naturally occurring congeners staurosporine (1) and K252a (2) have been the focus of considerable research. The PI states that this proposal describes: (A) preliminary studies in which a concise synthesis of 2 has been achieved (eleven synthetic operations, longest linear sequence of seven steps); and (B) the application of this chemistry to the synthesis of 1 and analogs of 2 (i.e., 3). It is reported that the latter analogs are targeted for use as probes in a Chinese Hamster Ovary Cell assay developed at Yale and the capping agent in a combinatorial peptide library that can be utilized to screen a wide range of analogs for PK isozyme specificity. It is noted that finally, efforts toward K252a have resulted in the development of novel carbenoid reactions for which further research is proposed.
描述:PI报告细胞信号中断 通过蛋白激酶(PK)功能障碍的转导与 几种疾病状态的发作,包括:类风湿性关节炎,全身性 红斑狼疮、糖尿病和阿尔茨海默病。 他指出 虽然PK抑制是化疗的逻辑目标, 由于许多PK同工酶之间的结构同源性, 开发特异性的、因此在治疗上有用的抑制剂。 它 报告指出,在下列领域取得了一些具体成果: 吲哚并咔唑,因此原型天然存在的同系物 Staurosporine(1)和K252a(2)一直是相当多的焦点, research. PI指出,该提案描述了:(A)初步 研究,其中一个简洁的合成2已经实现(十一 合成操作,最长的线性序列的七个步骤);和(B) 将该化学方法应用于1和2的类似物的合成(即, 3)。 据报道,后者类似物被靶向用作探针 在耶鲁大学开发的中国卵巢细胞试验中, 可以利用组合肽文库中的试剂来筛选 广泛的PK同工酶特异性类似物。 值得注意的是,最后, 对K252a的努力导致了新类卡宾的开发 反应,建议进一步研究。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Rhodium carbenoid-initiated Claisen rearrangement: scope and mechanistic observations.
  • DOI:
    10.1021/ol990697x
  • 发表时间:
    1999-07
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    J. Wood;G. Moniz
  • 通讯作者:
    J. Wood;G. Moniz
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN L WOOD其他文献

JOHN L WOOD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN L WOOD', 18)}}的其他基金

Method and Strategy Development for the Synthesis of Physiologically Important Natural Products
合成具有生理重要性的天然产物的方法和策略开发
  • 批准号:
    10389539
  • 财政年份:
    2021
  • 资助金额:
    $ 22.14万
  • 项目类别:
Method and Strategy Development for the Synthesis of Physiologically Important Natural Products
合成具有生理重要性的天然产物的方法和策略开发
  • 批准号:
    10132361
  • 财政年份:
    2020
  • 资助金额:
    $ 22.14万
  • 项目类别:
Method and Strategy Development for the Synthesis of Physiologically Important Natural Products
合成具有生理重要性的天然产物的方法和策略开发
  • 批准号:
    10371896
  • 财政年份:
    2020
  • 资助金额:
    $ 22.14万
  • 项目类别:
Method and Strategy Development for the Synthesis of Physiologically Important Natural Products
合成具有生理重要性的天然产物的方法和策略开发
  • 批准号:
    10580775
  • 财政年份:
    2020
  • 资助金额:
    $ 22.14万
  • 项目类别:
Studies in the Synthesis of Physiologically Important
生理重要物质的合成研究
  • 批准号:
    7362069
  • 财政年份:
    2007
  • 资助金额:
    $ 22.14万
  • 项目类别:
Studies in the Synthesis of Physiologically Important
生理重要物质的合成研究
  • 批准号:
    6547101
  • 财政年份:
    2002
  • 资助金额:
    $ 22.14万
  • 项目类别:
Studies in the Synthesis of Physiologically Important
生理重要物质的合成研究
  • 批准号:
    7069986
  • 财政年份:
    2002
  • 资助金额:
    $ 22.14万
  • 项目类别:
Studies in the Synthesis of Physiologically Important
生理重要物质的合成研究
  • 批准号:
    6611357
  • 财政年份:
    2002
  • 资助金额:
    $ 22.14万
  • 项目类别:
Studies in the Synthesis of Physiologically Important
生理重要物质的合成研究
  • 批准号:
    6755957
  • 财政年份:
    2002
  • 资助金额:
    $ 22.14万
  • 项目类别:
Studies in the Synthesis of Physiologically Important
生理重要物质的合成研究
  • 批准号:
    6908180
  • 财政年份:
    2002
  • 资助金额:
    $ 22.14万
  • 项目类别:

相似海外基金

Autoimmune disorder in hereditary angioedema
遗传性血管性水肿中的自身免疫性疾病
  • 批准号:
    26460654
  • 财政年份:
    2014
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of lymphocyte transmigration across the blood-brain barrier using an in vitro model that mimics blood flow and simulates inflammatory conditions as observed in the most frequent autoimmune disorder of the central nervous system, multiple sclero
使用体外模型模拟血流并模拟在中枢神经系统最常见的自身免疫性疾病多发性硬化症中观察到的炎症状况,从而研究淋巴细胞跨血脑屏障的迁移机制
  • 批准号:
    235301825
  • 财政年份:
    2013
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Research Fellowships
The challenge for the development of therapy for autoimmune disorder by the establishment of artificial thymic medullary organ
人工胸腺髓质器官的建立对自身免疫性疾病治疗发展的挑战
  • 批准号:
    23659241
  • 财政年份:
    2011
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了